TSE Systems and NeuroLux Announce Partnership Integrating Wireless Optogenetics with In-Vivo Phenotyping Platforms

Integrating Wireless Optogenetics with In-Vivo Phenotyping Platforms

TSE Systems, a leader in advanced preclinical research equipment for metabolic and behavioral research, and NeuroLux, the world leader, and developer of battery-free wireless optogenetics implants for preclinical research, today announced an exclusive partnership that will change in-vivo animal science.

NeuroLux is an early-stage company with a proven, patented preclinical technology platform that is based on more than a decade of engineering research. The company has supplied more than 250 complete systems and 25,000 wireless implantable devices to nearly 100 institutions in 10 countries worldwide.

Utilizing Neurolux’s breakthrough wireless technology for optogenetics and programmable pharmacology, scientists are now able to control neural circuits in freely moving animals with minimal injury to sensitive tissues and without interference from tethering hardware.

The combination of TSE Systems’ PhenoMaster or IntelliCage and the NeuroLux wireless optogenetics implants greatly expands research opportunities into many frontier areas of neuroscience and clinical medicine, through new tools for optogentics, pharmacology, photopharmacology and other techniques for neuromodulation.

This partnership comes ahead of the upcoming Society for Neuroscience 2021 (SfN) conference in Chicago, where both companies will showcase NeuroLux’s wireless optogenetics integrations with the TSE Systems equipment.